Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients
- Conditions
- Patients Transplanted With NiCord/CordIn (Omidubicel)
- Interventions
- Genetic: NiCord®/CordIn™ (omidubicel)
- Registration Number
- NCT02039557
- Lead Sponsor
- Gamida Cell ltd
- Brief Summary
This is an observational study that will monitor clinical outcomes of patients who have received a NiCord®/CordIn™ (omidubicel) transplant as part of a GC clinical interventional study and meet the eligibility criteria for this Long Term Follow Up study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description NiCord®/CordIn™ (omidubicel) transplanted NiCord®/CordIn™ (omidubicel) Anyone who signed the consent for this study received a NiCord®/CordIn™ (omidubicel) infusion as part of a GC clinical interventional study, and completed the interventional study Day 365 status assessment.
- Primary Outcome Measures
Name Time Method long term sustained chimerism of NiCord®/CordIn™ (omidubicel) transplantation 5 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (9)
UCSF Benioff Children's Hospital
🇺🇸Oakland, California, United States
University Hospital Vall D'Hebron
🇪🇸Barcelona, Spain
Hospital Universitario La Fe
🇪🇸Valencia, Spain
National University Cancer Institute
🇸🇬Singapore, Singapore
Singapore General Hospital
🇸🇬Singapore, Singapore
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Vanderbilt
🇺🇸Nashville, Tennessee, United States
Loyola University, Cardinal Bernardin Cancer Center
🇺🇸Maywood, Illinois, United States
University Medical Center Utrecht
🇳🇱Utrecht, Netherlands